Clinical Trials

BreastDermatologicGastrointestinalGenitourinaryGynecologic

77 enrolled

Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Melanoma, Neoplasm Metastasis, Colorectal Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT03425565 2024-04-12

PEACOCC

48 enrolled

Clear Cell Tumor

NCT06308406 2024-04-11

A Phase Ib/II Clinical Study of HRS-1167 in Combination With Bevacizumab in Patients With Recurrent Ovarian Cancer

54 enrolled

Ovarian Neoplasms

NCT06341855 2024-04-02

Exploring the Potential of ctDNA-MRD for Recurrence Surveillance and Prognostic Evaluation in High-risk Endometrial Cancer

100 enrolled

Endometrial Neoplasms

NCT05311618 2024-04-01

Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

71 enrolled

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Melanoma, Mesothelioma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT04929015 2024-03-21

Peritoneal Carcinomatosis Leveraging ctDNA Guided Treatment in GI Cancer Study (PERICLES Study)

30 enrolled

Digestive System Neoplasms, Carcinoma, Hepatocellular, Peritoneal Neoplasms

NCT05305820 2024-03-21

PANO

36 enrolled

Appendiceal Neoplasms, Colonic Neoplasms, Ovarian Neoplasms, Rectal Neoplasms

NCT06242522 2024-03-15

FERTILAVE

50 enrolled

Gestational Trophoblastic Tumours

NCT05368207 2024-03-13

Pemb-HT

1 enrolled

Ovarian Neoplasms, Carcinoma, Small Cell

NCT04766320 2024-03-06

Study on TIL for the Treatment of r/r Gynecologic Tumors

15 enrolled

Gynecologic Cancer

NCT04780217 2024-03-04

Intravenous T3011 Given as a Single Agent and in Combination With Other Therapy in Subjects With Advanced Solid Tumors

42 enrolled

Carcinoma, Hepatocellular, Ovarian Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT04512209 2024-02-28

DCE-MRI

44 enrolled

Colonic Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Peritoneal Neoplasms

NCT06031493 2024-02-28

PROVIDENCE

Phase 4 Unknown

122 enrolled

GynecologicOther

Uterine Cervical Neoplasms, Sexual Dysfunction, Physiological

NCT06279832 2024-02-28

Romantic

1,000 enrolled

Endometrial Neoplasms

NCT06281860 2024-02-28

PITHAC

BreastGastrointestinalGynecologicOther solid neoplasmThoracic

39 enrolled

Mesothelioma, Malignant, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Ovarian Neoplasms, Stomach Neoplasms

NCT05371223 2024-02-26

Nab-PIPAC

38 enrolled

Pancreatic Neoplasms, Peritoneal Neoplasms

NCT06277947 2024-02-26

GARD-HIPEC

92 enrolled

Carcinoma, Ovarian Epithelial

NCT05701735 2024-02-23

CECIL

45 enrolled

Uterine Cervical Neoplasms, Renal Insufficiency

NCT05300711 2024-02-22

Preventing Ovarian Cancer Through Oportunistic Salpingectomy at the Time of Colorectal Surgery

240 enrolled

Ovarian Neoplasms

NCT05737797 2024-02-22

NIECE

100 enrolled

Endometrial Neoplasms, Microsatellite Instability

NCT06273501 2024-02-22

POSVUC

20 enrolled

Lymphatic Metastasis, Vulvar Neoplasms

NCT03924466 2024-02-16

VUBAR

BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

55 enrolled

Biliary Tract Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Pancreatic Neoplasms, Prostatic Neoplasms, Salivary Gland Neoplasms, Stomach Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

NCT06263062 2024-02-16

Management With Fear of Cancer in Women Undergoing Colposcopy: Randomized Controlled Study

60 enrolled

Pathophobia, Uterine Cervical Neoplasms

NCT06261879 2024-02-15

Non-invasive Biomarker Discovery for Pre-cervical or/and Cervical Cancer--ACTN4 and Other Biomarkers in Menstrual Blood

300 enrolled

Uterine Cervical Neoplasms

NCT06261892 2024-02-15

Non-invasive Biomarker Discovery for Pre-cervical or/and Cervical Cancer-HPV DNA and Other Biomarkers in Urine

300 enrolled

Uterine Cervical Neoplasms

NCT04145388 2024-02-14

Family History Study on Cancer Risk

BreastGastrointestinalGynecologic

18,623 enrolled

Breast Neoplasms, Colorectal Neoplasms, Hereditary Nonpolyposis, Neoplasms, Ovarian Neoplasms, Colorectal Neoplasms, Genetic Predisposition to Disease

NCT02730923 2024-02-13

VICTORIA

72 enrolled

Carcinoma, Endometrial Neoplasms

NCT05829057 2024-02-13

The IIT Study of Evaluation of P-IL-2 Single Agent and With Anti-PD-1

GastrointestinalGenitourinaryGynecologicThoracic

10 enrolled

Urinary Bladder Neoplasms, Esophageal Neoplasms, Liver Neoplasms, Neoplasms, Ovarian Neoplasms, Small Cell Lung Carcinoma

NCT06250686 2024-02-09

BENITA

185 enrolled

Fatigue, Muscular Atrophy, Ovarian Neoplasms, Malnutrition

NCT02820506 2024-02-08

SENTIREC II

300 enrolled

Uterine Cervical Neoplasms, Uterine Neoplasms

NCT03549273 2024-02-07

Evaluation Glizigen® and Ocoxin®-Viusid® in High-grade Cervical Intraepithelial Lesions

62 enrolled

Carcinoma, Uterine Cervical Dysplasia, Neoplasms, Neoplasms, Glandular and Epithelial

NCT04149691 2024-02-07

Safety, Tolerability and Pharmacokinetics of Oral CPL304110, in Adult Subjects With Advanced Solid Malignancies

GastrointestinalGenitourinaryGynecologicSarcoma

42 enrolled

Urinary Bladder Neoplasms, Carcinoma, Neoplasms, Sarcoma, Stomach Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

NCT05916911 2024-02-07

Evaluation Of The Efficacy Of The Combination Of GLIZIGEN® Oral Solution 1/Day And Vaginal Gel 1/Night For 2 Months In Patients With Cervical Intraepithelial Neoplasia Grade 1 (LSIL/CIN-1) Caused By High-Risk Human Papillomavirus (HPV-AR)

Phase 4 Unknown

120 enrolled

Squamous Intraepithelial Lesions, Papillomavirus Infections

NCT06069648 2024-02-07

Effects of Decision Aids on the Participation of South Asian Women in Cervical Cancer Screening

270 enrolled

Uterine Cervical Neoplasms

NCT05189028 2024-02-06

Study of Neoadjuvant Chemotherapy Versus Definite Concurrent Chemoradiotherapy for Locally Advanced Bulk Cervical Cancer

Phase 3 Unknown

290 enrolled

Uterine Cervical Neoplasms

NCT06243185 2024-02-06

Dalpiciclib Combined With Letrozole in HR+/HER2 - Gynecologic Solid Tumors

30 enrolled

Ovarian Neoplasms

NCT06241105 2024-02-05

Lenvatinib Plus Toripalimab for Platinum-Resistant Recurrent Ovarian Cancer

69 enrolled

Ovarian Neoplasms

NCT05787535 2024-02-02

HRYZ-T101 TCR-T Cell for HPV-18 Positive Advanced Solid Tumor

GastrointestinalGenitourinaryGynecologicHead & Neck

17 enrolled

Squamous Cell Carcinoma of Head and Neck, Anus Neoplasms, Uterine Cervical Neoplasms, Oropharyngeal Neoplasms, Penile Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms

NCT03016338 2024-01-30

Study of Niraparib and TSR-042 in Recurrent Endometrial Cancer

51 enrolled

Endometrial Neoplasms

NCT05489926 2024-01-26

A Study to Explore Pamiparib Treatment in Epithelial Ovarian Cancer After Prior PARP Inhibitor Exposure

15 enrolled

Carcinoma, Ovarian Epithelial

NCT06223308 2024-01-25

A Study Evaluating the Safety and Efficacy of HB0028 in Subjects With Advanced Solid Tumors

54 enrolled

Uterine Cervical Neoplasms

NCT05916690 2024-01-19

Electrochemotherapy for the Treatment of Vulvar Cancer

20 enrolled

Vulvar Neoplasms

NCT05084677 2024-01-18

Toripalimab Combined With Concurrent Chemoradiotherapy in Cervical Cancer

96 enrolled

Uterine Cervical Neoplasms

NCT02489006 2024-01-17

NEO

71 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05065021 2024-01-17

Using Genetic Profile to Determine the Treatment for Patients With Ovarian Cancer Who Previously Received a PARP-inhibitor

40 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06171581 2024-01-09

Effect of Stress Ball Use on Anxiety Level During Endometrial Biopsy Procedure

70 enrolled

Endometrial Hyperplasia, Endometrial Neoplasms

NCT04683549 2024-01-08

HPV-RICCO

30 enrolled

Uterine Cervical Neoplasms

NCT03935256 2023-12-18

Adjuvant Sequential & Concurrent CarboTaxol + Radiotherapy for High Risk Endometrial Cancer

24 enrolled